About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Logout
Obstetrics and Gynegology2020№7
Treatment for female external genital...

Treatment for female external genital lichen sclerosus: from standards to innovations

DOI
https://dx.doi.org/10.18565/aig.2020.7.37-46

Sokolova A.V., Apolikhina I.A.

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia, Moscow, Russia
Lichen sclerosus is one of the most common female external genital diseases. The limiting factor for the success of treatment for vulvar lichen sclerosus is a lack of consensus on the etiopathogenesis of the disease and accordingly targeted treatments. Topical glucocorticosteroids and calcineurin inhibitors are now the first-line therapy. Despite a variety of drugs for the treatment of vulvar lichen sclerosus, there are more and more cases of resistance and adverse reactions to traditional therapy, and considering the young age of patients, the search for new technologies in the treatment of vulvar lichen sclerosus is becoming urgent. The article reviews methods for treating the disease in accordance with international protocols and Russian recommendations. In addition, it describes minimally invasive techniques, such as high-frequency focused ultrasound (HIFU), photothermal vulvar tissue reconstruction using carbon dioxide, erbium, and neodymium lasers, platelet-rich plasma (PRP), and autologous stem-cell transplantation, which are currently actively used and have a great therapeutic potential to influence the foci of lichen sclerosus.

Keywords

vulvar lichen sclerosus
topical corticosteroids
laser exxposure
PRP
HIFU
Full text (in Russian)

References

  1. Jones R.W., Scurry J., Neill S., MacLean A.B. Guidelines for the follow-up of women with vulvar lichen sclerosus in specialist clinics. Am. J. Obstet. Gynecol. 2008; 198(5): 496. e1-496. e3. https://dx.doi.org/10.1016/j.ajog.2007.05.031.
  2. Tran D.A., Tan X., Macri C.J., Goldstein A.T., Fu S.W. Lichen sclerosus: an autoimmunopathogenic and genomic enigma with emerging genetic and immune targets. Int. J. Biol. Sci. 2019; 15(7): 1429-39. https://dx.doi.org/10.7150/ijbs.34613.
  3. Howard A., Dean D., Cooper S., Kirtshig G., Wojnarowska F. Circulating basement membrane zone antibodies are found in lichen sclerosus of the vulva. Australas. J. Dermatol. 2004; 45(1): 12-5. https://dx.doi.org/10.1111/j.1440-0960.2004.00026.x.
  4. Clifton M.M., Garner I.B., Kohler S., Smoller B.R. Immunohistochemical evaluation of androgen receptors in genital and extragenital lichen sclerosus: evidence for loss of androgen receptors in lesional epidermis. J. Am. Acad. Dermatol. 1999; 41(1): 43-6. https://dx.doi.org/10.1016/s0190-9622 (99)70404-4.
  5. Higgins C.A., Cruickshank M.E. A population-based case-control study of aetiological factors associated with vulvar lichen sclerosus. J. Obstet. Gynaecol. 2012; 32(3): 271-5. https://dx.doi.org/10.3109/01443615.2011.649320.
  6. Nasca M.R., Lacarrubba F., Micali G. Human papillomavirus infection and lichen sclerosus: coincidence or link? Int. J. Dermatol. 2018; 57(5): 611-24. https://dx.doi.org/10.1111/ijd.13933.
  7. Aidé S., Lattario F.R., Almeida G., do Val I.C., da Costa Carvalho M. Epstein-Barr virus and human papillomavirus infection in vulvar lichen sclerosus. J. Low. Genit. Tract. Dis. 2010; 14(4): 319-22. https://dx.doi.org/10.1097/LGT.0b013e3181d734f1.
  8. Eisendle K., Grabner T., Kutzner H., Zelger B. Possible role of Borrelia burgdorferi sensu lato infection in lichen sclerosus. Arch. Dermatol. 2008; 144(5): 591-8. https://dx.doi.org/10.1001/archderm.144.5.591.
  9. Реуцкая М.А., Кулинич С.И. Новые подходы к диагностике и лечению заболеваний вульвы. Сибирский медицинский журнал. 2011; 6: 277-9. [Reutskaya M.A., Kulinich S.I. Vulvar diseases and their interrelation with genital infection. Siberian Medical Journal. 2011; 6: 277-9 (in Russian)].
  10. Kirtschig G., Cooper S., Aberer W., Günthert A, Becker K., Jasaitiene D. et al. Evidence-based (S3) guideline on (anogenital) lichen sclerosus. J. Eur. Acad. Dermatol. Venereol. 2017;31(2): e81-3. https://dx.doi.org/10.1111/jdv.13740.
  11. Kravvas G., Shim T.N., Doiron P.R., Freeman A., Jameson C., Minhas S. et al. The diagnosis and management of male genital lichen sclerosus: a retrospective review of 301 patients. J. Eur. Acad. Dermatol. Venereol. 2018; 32(1): 91-5. https://dx.doi.org/10.1111/jdv.14488.
  12. Marfatia Y., Surani A., Baxi R. Genital lichen sclerosus et atrophicus in females: An update. Indian. J. Sex. Transm. Dis. AIDS. 2019; 40(1): 6-12. https://dx.doi.org/10.4103/ijstd.IJSTD_23_19.
  13. Sherman V., McPherson T., Baldo M., Salim A., Gao X.H., Wojnarowska F. The high rate of familial lichen sclerosus suggests a genetic contribution: an observational cohort study. J. Eur. Acad. Dermatol. Venereol. 2010; 24(9): 1031-4. https://dx.doi.org/10.1111/j.1468-3083.2010.03572.x.
  14. Virgili A., Borghi A., Cazzaniga S., Di Landro A., Naldi L., Minghetti S. et al.; GLS Italian Study Group. New insights into potential risk factors and associations in genital lichen sclerosus: Data from a multicentre Italian study on 729 consecutive cases. J. Eur. Acad. Dermatol. Venereol. 2017; 31(4): 699-704. https://dx.doi.org/10.1111/jdv.13867.
  15. Powell J.J., Wojnarowska F. Lichen sclerosus. Lancet. 1999; 353(9166): 1777-83. https://dx.doi.org/10.1016/S0140-6736(98)08228-2
  16. Burns P.B., Rohrich R.J., Chung K.C. The levels of evidence and their role in evidence-based medicine. Plast. Reconstr. Surg. 2011; 128(1): 305-10. https://dx.doi.org/10.1097/PRS.0b013e318219c171.
  17. Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд. М.: Деловой экспресс; 2016. 768 с. [Federal clinical guidelines. Dermatovenerology 2015: Diseases of the skin. Sexually transmitted infections 5th edition revised and supplemented. Russian Federation. Moscow Business express; 2016. 768 p.(in Russian)].
  18. Lewis F.M., Tatnall F.M., Velangi S.S., Bunker C.B., Kumar A., Brackenbury F. et al. British Association of Dermatologists guidelines for the management of lichen sclerosus. Br. J. Dermatol. 2018; 178(4): 839-53. https://dx.doi.org/10.1111/bjd.16241
  19. Virgili A., Gorghi A., Toni G., Minghetti S., Corazza M. First randomized trial on clobetasol propionate and mometasone furoate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability. Br. J. Dermatol. 2014; 171(2): 388-96. https://dx.doi.org/10.1111/bjd.12910.
  20. Ventolini C., Swenson K.M., Galloway M.L. Lichen sclerosus: a 5-year follow-up after topical, subdermal, or combined therapy. J. Low. Genit. Tract. Dis. 2012; 16(3): 271-4.
  21. Baggish M.S., Ventolini C. Lichen sclerosus: Subdermal steroid injection therapy. A large, long-term follow-up study. J. Gynecol. Surg. 2006; 22(4):, 137-41. https://dx.doi.org/10.1089/gyn.2006.22.137.
  22. Von Krogh G., Dahlman-Ghozlan K., Syrjanen S. Potential human papillomavirus reactivation following topical corticosteroid therapy of genital lichen sclerosus and erosive lichen planus. J. Eur. Acad. Dermatol. Venereol. 2002; 16(2): 130-3. https://dx.doi.org/10.1046/j.1468-3083.2002.00420.x
  23. Strittmatter H.J., Hengge U.R., Blecken S.R. Calcineurin antagonists in vulvar lichen sclerosus. Arch. Gynecol. Obstet. 2006; 274(5): 266-70. https://dx.doi.org/10.1007/s00404-006-0151-1.
  24. Funaro D., Lovett A., Leroux N., Powell J. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. J. Am. Acad. Dermatol. 2014; 71(1): 84-91. https://dx.doi.org/10.1016/j.jaad.2014.02.019.
  25. Hodgins M.B., Mackie R.M., Spike R.C., Maclean A. An immunohistochemical study of androgen, oestrogen and progesterone receptors in the vulva and vagina. Br. J. Obstet. Gynaecol. 1998; 105(2): 216-22. https://dx.doi.org/10.1111/j.1471-0528.1998.tb10056.x.
  26. Bracco G.L., Carli P., Sonni L., Maestrini G., De Marco A., Taddei G.L., Cattaneo A. Clinical and histologic effects of topical treatments of vulval lichen sclerosus. A critical evaluation. J. Reprod. Med. 1993; 38(1):37-40.
  27. Preti M., Vieira-Baptista P., Digesu G.A., Bretschneider C.E., Damaser M., Demirkesen O. et al. The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: An ICS/ISSVD best practice consensus document. Neurourol. Urodyn. 2019; 38(3): 1009-23.https://dx.doi.org/10.1097/LGT.0000000000000462.
  28. Bizjak Ogrinc U., Senčar S., Luzar B., Lukanović A. Efficacy of non-ablative laser therapy for lichen sclerosus: a randomized controlled trial. J. Obstet. Gynaecol. Can. 2019; 41(12): 1717-25. https://dx.doi.org/10.1016/j.jogc.2019.01.023
  29. Lee A., Lim A., Fischer G. Fractional carbon dioxide laser in recalcitrant vulval lichen sclerosus. Australas. J. Dermatol. 2016; 57: 39-43. https://dx.doi.org/10.1111/ ajd.12305.
  30. Карабут М.М., Гладкова Н.Д., Фельдштейн Ф.И. Фракционный лазерный фототермолиз в лечении кожных дефектов: возможности и эффективность (обзор). Современные технологии в медицине. 2016; 8(2): 98-108. [Karabut М.М., Gladkova N.D., Feldchtein F.I. Fractional laser photothermolysis in the treatment of skin defects: possibilities and effectiveness (review). Sovremennye tehnologii v medicine 2016; 8(2): 98–108 (in Russian)].
  31. Arroyo C., Perez A., Muñoz L. Treatment of lichen sclerosus with Erbium:YAG Laser – an option to consider. J. Laser Health Academy. 2018; 1: S14. Available at: https://www.laserandhealthacademy.com/en/library/4725/cesar-arroyo-er-yag-treatment-of-lichen-sclerosus
  32. Gómez-Frieiro M., Laynez-Herrero E. Use of Er:YAG Laser in the treatment of vulvar lichen sclerosus. Int. J. Women's Dermatol. 2019; 5(5): 340-4. https://dx.doi.org/10.1016/j.ijwd.2019.05.007.
  33. Windahl T. Is carbon dioxide laser treatment of lichen sclerosus effective in the long run?, Scandinavian J. Urol. Nephrol. 2006; 40(3): 208-11. https://dx.doi.org/10.1080/00365590600589666.
  34. Pagano T., Conforti A., Buonfantino C., Schettini F., Vallone R., Gallo A. et al. Effect of rescue fractional microablative CO2 laser on symptoms and sexual dysfunction in women affected by vulvar lichen sclerosus resistant to long-term use of topic corticosteroid: a prospective longitudinal study. Menopause. 2020; 27(4): 418-22. https://dx.doi.org/10.1097/GME.0000000000001482.
  35. Хашукоева А.З., Отдельнова О.Б., Купеева Е.С. Фотодинамическая терапия дистрофических заболеваний вульвы в сочетании с папилломавирусной инфекцией. Лечение и профилактика. 2012; 1: 78-80. [Khashukoeva A.Z, Kupeeva E.S., Otdelnova O.B. PDT of dystrophic vulvar diseases in combination with papillomavirus infection, Treatment and prevention. 2012; 1: 78-80 (in Russian)].
  36. Новикова Е.Г., Соколов В.В., Сидорова И.С., Чулкова Е.А. Флюоресцентная диагностика и фотодинамическая терапия фоновых и предраковых заболеваний вульвы с применением 20% мази «Аласенс». Российский онкологический журнал. 2009; 2: 12-9. [Novikova E.G., Sokolov V.V., Sidorova I.S., Chulkova E.A. Fluorescence diagnosis and photodynamic therapy of background and pre-cancer vulvar diseases with 20% Alasens ointment, Rossiiskii onkologicheskii zhurnal. 2009; 2: 12-9. (in Russian)].
  37. Shi L., Miao F., Zhang L.L., Zhang G.L.,Wang P.R., Ji J. et al. Comparison of 5-aminolevulinic acid photodynamic therapy and clobetasol propionate in treatment of vulvar lichen sclerosus. Acta Derm. Venereol. 2016; 96(5): 684-8. https://dx.doi.org/10.2340/00015555-2341.
  38. Krapf J.M., Mitchell L., Holton M.A., Goldstein A.T. Vulvar Lichen Sclerosus: Current Perspectives. Int. J. Womens Health. 2020; 12: 11-20. https://dx.doi.org/10.2147/IJWH.S191200.
  39. Marx R. Platelet-rich plasma (PRP): What is PRP and what is not PRP? Implant. Dent. 2001; 10(4): 225-8. https://dx.doi.org/10.1097/00008505-200110000-00002.
  40. Аполихина И.А., Соколова А.В., Педанов А.М., Иванова Е.В. Применение богатой тромбоцитами плазмы в эстетической гинекологии. Учебное пособие. М.: Меркурий; 2019. 100 с. [Apolikhina I.A, Sokolova A.V., Pedanov A.M., Ivanova E.V. The use of platelet-rich plasma in aesthetic gynecology. Moscow: Mercury; 2019. 100 p. (in Russian)].
  41. Tedesco M., Pranteda G., Chichierchia G., Paolino G., Latini A., Orsini D. et al. The use of PRP (platelet‐rich plasma) in patients affected by genital lichen sclerosus: clinical analysis and results. J. Eur. Acad. Dermatol. Venereol. 2019; 33(2): e58-9. https://dx.doi.org/10.1111/jdv.15190.
  42. Turzi Antoine & Regen Lab team. PRP standardisation & cells therapies. (PRP – Platelet Rich Plasma). Biobridge Foundation Editions; 3 Jan. 2018. 96p.
  43. Casabona F., Priano V., Vallerino V., Cogliandro A., Lavagnino G. New surgical approach to lichen sclerosus of the vulva: the role of adipose-derived mesenchymal cells and platelet-rich plasma in tissue regeneration. Plast. Reconstr. Surg. 2010; 126(4): 210e-211e. https://dx.doi.org/10.1097/PRS.0b013e3181ea9386.
  44. Boero V., Brambilla M., Sipio E., Liverani C.A., Di Martino M., Agnoli B. et al. Vulvar lichen sclerosus: a new regenerative approach through fat grafting. Gynecol. Oncol. 2015; 139(3): 471-5. https://dx.doi.org/10.1016/j.ygyno.2015.10.014.
  45. Monreal J. Safety and efficacy of stromal vascular fraction enriched Fft grafting therapy for vulvar lichen sclerosus. Cureus. 2020; 12(2): e7096. https://dx.doi.org/10.7759/cureus.7096.
  46. Pinheiro N.M., Crema V.O., Millan B.M., Carvalho F.A., Mendonça A.C. Comparison of the effects of carboxytherapy and radiofrequency on skin rejuvenation. J. Cosmet. Laser Ther. 2015; 17(3): 156-61. https://dx.doi.org/10.3109/14764172.2014.1003238.

Received 29.04.2020

Accepted 25.06.2020

About the Authors

Inna A. Apolikhina, MD, obstetrician&gynecologist, professor, National Medical Research Center for Obstetrics, Gynecology and Perinatology named after V.I. Kulakov, Moscow, Russian Federation; First Moscow State Medical University named after I.M. Sechenov, Moscow, Russian Federation.
Тel.: +7(495)735-10-55. E-mail: apolikhina@inbox.ru.
4, Oparina str., Moscow, 117997, Russian Federation.
Anastasia V. Sokolova, MD, obstetrician&gynecologist, post-graduate student National Medical Research Center for Obstetrics, Gynecology and Perinatology named
after V.I. Kulakov, Moscow, Russian Federation. Тel.: +7(915)455-31-32. E-mail: stasia0590@mail.ru.
4, Oparina str., Moscow, 117997, Russian Federation

For citation: Sokolova A.V., Apolikhina I.A. Treatment for female external genital lichen sclerosus: from standards to innovations.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2020; 7: 37-46 (in Russian).
https://dx.doi.org/10.18565/aig.2020.7.37-46

Similar Articles

№1 / 2021
Moskvicheva L.I.
Possibilities of using high-intensity focused ultrasound therapy in patients with endometriosis
№7 / 2023
Gorbunova E.A., Apolikhina I.A., Ramazanova M.O.
Application of CO2-fraction laser photothermolysis in gynecological practice
№11 / 2020
Kovalev M.V., Vartanyan E.V., Dobrokhotova Yu.E., Tsaturova K.A., Devyatova E.A.
Use of autologous platelet­rich plasma in infertility and miscarriage
№1 / 2023
Moskvicheva L.I.
The role of high-intensity focused ultrasound treatment in patients with uterine myoma
№12 / 2020
Apolikhina I.A., Malyshkina D.A., Teterina T.A.
Innovative approaches to high-intensity focused ultrasound treatment for vulvar diseases
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.